Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report sent to investors on Sunday. The firm issued a hold rating on the stock.

A number of other equities research analysts also recently commented on ONCT. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Northland Capmk downgraded Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Northland Securities reissued a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright reduced their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Stock Performance

ONCT opened at $1.62 on Friday. The company has a market capitalization of $4.80 million, a PE ratio of -0.13 and a beta of 1.33. The stock’s fifty day moving average is $2.08 and its 200-day moving average is $5.57. Oncternal Therapeutics has a one year low of $1.05 and a one year high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.24 million. During the same period in the prior year, the company earned ($3.00) EPS. On average, equities research analysts forecast that Oncternal Therapeutics will post -12.43 EPS for the current fiscal year.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.